Claims for Patent: 10,406,236

Summary for Patent: 10,406,236

Title:	Single wall nanotube constructs and uses thereof
Abstract:	The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
Inventor(s):	Scheinberg; David A. (New York, NY), McDevitt; Michael R. (New York, NY), Antczak; Christophe (Arlington, MA), Chattopadhyay; Debjit (Pennington, NJ), May; Rena (Baltimore, MD), Njardarson; Jon (Tucson, AZ), Phillips; Mark Reid (New York, NY)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:	15/494,974
Patent Claims:	1. A method of treating a cancer in a subject, comprising: administering a soluble single wall carbon nanotube (SWNT) construct having the structure SWNT-(DNA.sub.1,2-(cDNA.sub.1-peptide).sub.m-(cDNA.sub.2-M*tetr- aazacyclododecane-1,4,7,10-tetra acetic acid (DOTA)).sub.n).sub.x, such that cDNA.sub.1 is linked to the peptide, cDNA.sub.2 is linked to DOTA and DNA.sub.1,2 is linked to the SWNT; and, wherein cDNA.sub.1 and cDNA.sub.2 independently are non-identical oligomers and DNA.sub.1,2 is an oligomer with a sequence complementary to cDNA.sub.1 and cDNA.sub.2; and, wherein said DNA.sub.1,2 is the sequence shown in SEQ ID NO: 1, said cDNA.sub.1 is the sequence shown in SEQ ID NO: 2 and said cDNA.sub.2 is the sequence shown in SEQ ID NO: 3; and, wherein said peptide is a targeting antibody or a targeting cyclic RGD or an NGR peptide ligand, M* is a radionuclide, x is 1 to 300; and m and n are independently 1 to 300; wherein, upon targeting cancer-associated cells with the peptide, said radionuclide M* has an anticancer effect against said cells thereby treating the cancer in the subject. 2. The method of claim 1, wherein the targeting antibody is a therapeutic antibody. 3. The method of claim 2, wherein the therapeutic antibody is rituximab, trastuzumab, or antinucleolin. 4. The method of claim 1, wherein M* is actinium-225, astatine-211, technetium-99, lutetium-177, gallium-68, holmium-166, bismuth-212, bismuth-213, yttrium-90, copper-64, copper-67, samarium-117, samarium-153, iodine-123, iodine-124, iodine-125, or iodine-131. 5. The method of claim 1, wherein said cancer associated cells are cancer cells or endothelial cells of the vasculature associated with the cancer.

Details for Patent 10,406,236

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-07-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-07-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-07-29
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2025-07-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2025-07-29